Investigator sites play a critical role in ensuring clinical trials are conducted appropriately, with a focus on participant safety, data quality and regulatory compliance.
The following 25 red flags highlight common areas that can lead to regulatory inspection issues. While individual issues may appear minor, recurring or systemic deficiencies can raise broader concerns about site oversight, compliance and data reliability.
- Failure to follow the approved protocol
- Enrolling ineligible subjects, incorrect visit windows, dosing or procedural errors.
- Common leading finding in FDA and EMA inspections.
- Missing, incomplete, or outdated informed consent forms
- ICFs not signed, missing pages, or not re-consented after amendment.
- Protocol deviation management deficiencies
- Poor documentation, failure to trend deviations, lack of corrective actions.
- Poor source data and Case Report Form (CRF) consistency
- Unverified CRFs, missing source documents, discrepancies between physical and electronic records.
- Delayed or incomplete Serious Adverse Event (SAE) reporting
- Late notifications, incomplete narratives, missing follow-up data.
- Inadequate documentation of concomitant medications
- Gaps in records that compromise safety interpretation.
- Investigator oversight deficiencies
- PI fails to supervise delegated tasks or review key trial data.
- Delegation of Authority (DoA) log errors
- Missing, incorrect, or outdated logs for site staff responsibilities.
- Insufficient training and qualification records
- Missing GCP training, outdated records, unqualified staff performing critical tasks.
- Investigational Product (IP) accountability problems
- Inaccurate receipt, dispensing, return records or temperature excursions.
- Data integrity issues
- Audit trail gaps, backdating entries, unexplained data changes.
- A significant red flag, especially with electronic systems.
- Missed source data verification (SDV)
- Inadequate comparison of source documents and entered data.
- Unaddressed monitoring findings
- Site fails to resolve sponsor or CRO monitoring queries or concerns.
- Consent process non-compliance
- Enrolling or dosing before proper consent is obtained.
- Failure to maintain trial master file (TMF) essential documents
- Missing key regulatory documents, poor version control.
- Poor quality of safety data submission documents
- Missing narratives, unreported events to regulators/IRB.
- HIPAA/GDPR or patient confidentiality breaches
- Improper storage or sharing of identifiable data.
- High frequency of unexplained protocol violations
- Suggests systemic site quality issues.
- Discrepant visit logs or enrolment dates
- Contradictory records that challenge data reliability.
- Poor handling of laboratory or diagnostic data
- Missing lab results, failure to document critical labs.
- Inadequate adjudication of safety signals at site level
- Site fails to escalate unexpected trends.
- Excessively high screen failure or zero AE reporting
- Anomalous metrics that could indicate data fabrication or avoidance bias.
- Lack of documented corrective and preventive actions (CAPA)
- Non-compliance issues without appropriate CAPA plans or evidence of implementation.
- Safety monitoring not conducted per protocol
- E.g., missed safety labs or follow-up on abnormal results.
- Record-keeping and essential document errors
- Lost or improperly archived documents; incomplete case histories.
Addressing these red flags proactively can help investigator sites strengthen compliance, support participant safety, and maintain the quality and reliability of clinical trial data.